Highlights: 7 months at JLABS @ Shanghai

By JLABS
Articles

Launched in June 2019, JLABS @ Shanghai has opened up its space and made available its resources to 40 start-ups, supporting their novel ideas with the aim of addressing some of the world’s most pressing healthcare challenges. Over the past seven months, our resident companies have won awards, announced IPOs, advanced their potentially transformational solutions through clinical trials, and raised funds from our JLABS Investor Hub members – there is no shortage of reasons to be proud!

Let’s look at some of these spotlight achievements.

Shanghai Companies

(按字母顺序排列 arranged in alphabetical order)

APRINOIA

APRINOIA Therapeutics announces a Phase 2 study of a novel diagnostics product for Alzheimer's Disease

 

APRINOIA Therapeutics advances a pipeline featuring three diagnostic and three therapeutic products, aimed at collectively targeting brain disorders associated with tau and alpha-synuclein.

In November, APRINOIA Therapeutics announced the initiation of a Phase 2 multicenter, multinational study in the US for its lead tau positron emission tomography (PET) tracer for Alzheimer's Disease (AD). The study aims to compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults. 1

In addition to this study, APRINOIA is also conducting various medical research studies with leading imaging centers worldwide, including studies with the aim to develop new AI-based tau PET image analytical tools.

APRINOIA CODE

Learn more about the company

BottomLines

Bridgebio

Bridge Biotherapeutics’ IPO raises US$35.8 million in Korea and pushes ahead with studies

 

Focused on therapeutic areas of high unmet medical needs such as ulcerative colitis, fibrotic diseases, and cancers, Bridge Biotherapeutics (288330:KOSDAQ) marked several impressive milestones since joining JLABS @ Shanghai.

 

  • In July 2019, the company entered into a collaboration and license agreement with Boehringer Ingelheim with a total potential value in excess of EUR 1.1 billion. The collaboration aims to develop an autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). 2
  • In December 2019, the company filed an investigational new drug application for a study of BBT-176, a clinical candidate of targeted lung cancer therapy that was discovered by Korea Research Institute of Chemical Technology and licensed to Bridge Biotherapeutics for further development. 3
  • Also in December, the company announced plans to initiate a Phase I study of BBT-401, a potent first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, in China. The study aimed to bring innovative potential treatment options to patients with ulcerative colitis and was cleared by the Center for Drug Evaluation of China's National Medical Products Administration. 4
  • The company rounded off the year with a listing on the Korean Stock Exchange, raising US$35.8 million in the initial public offering. It is valued at US$283 million. 5
  • In January 2020, the company announced FDA IND Clearance for BBT-176, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) for non-small cell lung cancer (NSCLC). 6

Bridgebio Code

Learn more about the company

BottomLines

 

DNX Logo

DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson

 

DNX Biopharmaceuticals is developing highly innovativeanti-cytokine therapeutics, including DNX-314 and DNX-114, addressing unmet medical needs for rare cancers,non-rare cancers, and IL-1 or TNF-α-mediated SystemicAutoinflammatory Diseases (SAIDS).

In February, DNX Biopharmaceuticals announced collaboration with the Lung Cancer Initiative at Johnson & Johnson. Under terms of the agreement, the Lung Cancer Initiative has taken an exclusive license to research, develop and commercialize novel molecules from within the DNX portfolio.

DNX CODE

Learn more about the company

BottomLines

 

Hepagene

Hepagene Therapeutics, Inc. receives FDA authorization to proceed with first-in-human Phase I study of HPG1860 for NASH in the US

 

Hepagene Therapeutics, Inc. devotes its drug discovery and development efforts to discovering, developing and delivering innovative medicines that help patients suffering from liver diseases, especially non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection and liver cancer.

In September 2019, Hepagene announced that the U.S. Food and Drug Administration (FDA) had reviewed its HPG1860 Investigational New Drug (IND) application for the treatment of Nonalcoholic steatohepatitis (NASH) and had provided authorization for the company to proceed with its planned Phase I study in the United States. HPG1860 is an investigational non-bile acid, potent, selective and full farnesoid X receptor (FXR) agonist.

Hepagene CODE

Learn more about the company

BottomLines

HighTide

HighTide Therapeutic enrolls its last patient in a clinical study targeting liver disease

 

HighTide Therapeutics is dedicated to the discovery and development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, and is currently looking to address this huge unmet medical need.

In October, HighTide Therapeutics announced the last patient enrollment in a proof-of-concept and dose-ranging study investigating the efficacy and safety of HTD1801, a new molecular entity being developed for the treatment of complex liver diseases, nonalcoholic steatohepatitis (NASH) and PSC.7 The study results are expected in early 2020.

HighTide Code

Learn more about the company

BottomLines

Holmusk

Holmusk partners with Janssen R&D; to develop digital mental health strategy in China

 

Holmusk leverages real-world data to address mental health issues and aims to create the largest Real World Evidence (RWE) platform in behavioral health that incorporates electronic health record systems and digital health data gathered outside of clinician visits to create a longitudinal real-world behavioral health database.

In June 2019, Holmusk signed a Memorandum of Understanding (MoU) with Janssen (China) Research & Development to explore the development of a digital mental health strategy in China.8 Holmusk and Janssen aim to focus on generating insights from real-world data on depression and other mental health disorders to develop novel, scalable solutions to address the increasing burden of disease in China. The two organizations also aim to identify areas of unmet needs that a digital platform can enhance, and define the supporting, prioritized functionality based on the Janssen Neuroscience portfolio in China.

Holmusk was also selected as a Technology Pioneer, one of 56 tech firms that are shaping their industry and their region in new and exciting ways9, at the World Economic Forum 2019.

Holmusk CODE

Learn more about the company

BottomLines

Insilico

Insilico Medicine enters into a research collaboration with Pfizer Inc. to explore a novel data and AI system for potential therapeutic targets

 

Insilico Medicine focuses on generative models, reinforcement learning (RL), and other modern machine-learning techniques for the generation of new molecular structures with specified parameters, the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes.

In January 2020, Insilico Medicine entered into a research collaboration with Pfizer, Inc. (NYSE: PFE) to utilize Insilico's machine-learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases. 10

Also in January, Insilico Medicine entered into a collaboration with Beiersdorf to jointly discover novel, safe bioactive ingredients for a specific skin indication at an unparalleled pace, that will serve as the basis for developing appropriate skincare products. 11

Insilico_medicine_CODE

Learn more about the company

BottomLines

NDR

NDR Medical wins US$150,000 for its AI-driven robotics system aimed at enhancing minimally invasive surgery

 

NDR Medical integrates artificial intelligence and precision robotics with the aim to speed up the diagnosis of critical illnesses. The company has developed the first AI-automated surgical robotics and medical device to adapt an inverted Delta robot design for surgical applications. The system ensures accuracy of up to +/-3mm and is developed with the aim of supporting clinicians during minimally invasive procedures, automating the process of aligning the trajectory of the needle from the surface of the skin to the targeted point. NDR Medical hopes the system will improve early stage detection and diagnosis of lung cancer. 12

In October 2019, the company won the 2019 MedTech Innovator Asia Pacific Grand Prize in Singapore and took home an award of US$150,000 in non-dilutive cash. More than 170 applicants participated in the competition. 13

NDR CODE

Learn more about the company

BottomLines

 

JLABS

1 https://www.prnewswire.com/news-releases/initiation-of-a-phase-2-multicenter-study-of-18f-apn-1607-a-novel-diagnostic-pet-imaging-tracer-for-the-characterization-of-tau-burden-in-alzheimers-disease-300962816.html

2 https://www.boehringer-ingelheim.com/press-release/collaboration-bridge-biotherapeutics

3 https://www.prnewswire.com/news-releases/bridge-biotherapeutics-files-investigational-new-drug-application-for-bbt-176-an-egfr-tki-for-nsclc-300978114.html

4 https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-china-nmpa-clearance-of-ind-for-bbt-401-a-pellino-1-inhibitor-for-uc-300979419.html

5 https://www.biocentury.com/article/304091/deal-with-boehringer-pending-first-in-class-readouts-help-bridge-raise-36m-in-kosdaq-ipo

6 https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-fda-ind-clearance-for-bbt-176-an-egfr-tki-for-nsclc-300989424.html

7 https://www.prnewswire.com/news-releases/hightide-therapeutics-announces-completion-of-enrollment-in-phase-2a-nash-study-of-htd1801-300941467.html?tc=eml_cleartime

8 https://www.mobihealthnews.com/content/asia-pacific/holmusk-and-janssen-r-d-partner-develop-digital-mental-health-strategy-china

9 https://www.weforum.org/press/2019/07/meet-the-2019-world-economic-forum-technology-pioneers/

10 https://www.biospace.com/article/releases/insilico-enters-into-research-collaboration-with-pfizer-inc-to-explore-novel-data-and-artificial-intelligence-system-for-potential-therapeutic-targets/

11 https://www.beiersdorf.com/newsroom/press-releases/all-press-releases/2020/01/08-beiersdorf-and-insilico-medicine-employ-ai-technology-in-computer-simulated-skin-research

12 https://jlabs.jnjinnovation.com/JLABSNavigator#/
company/NDR_Medical_Technology_Pte_Ltd

13 https://www.biospectrumasia.com/news/54/14654/ndr-medical-titled-2019-apac-medtech-innovator-with-inochi-care-as-runner-up.html